The innate immune stimulant Amplimune® is safe to administer to young feedlot cattle.

BACKGROUND: Infectious disease has a significant impact on livestock production. Availability of alternatives to antibiotics to prevent and treat disease is required to reduce reliance on antibiotics while not impacting animal welfare. Innate immune stimulants, such as mycobacterium cell wall fractions (MCWF), are used as alternatives to antibiotics for the treatment and prevention of infectious disease in a number of species including cattle, horses and dogs. This study aimed to evaluate the safety of Amplimune®, an MCWF-based immune stimulant, for weaner Angus cattle. METHODS: On day -1 and 0, sixty mixed-sex Angus weaner cattle were transported for 6 h before being inducted and housed in a large single pen, simulating feedlot induction conditions. The cattle were assigned to one of six treatment groups (n = 10 per group): 2 mL Amplimune intramuscularly (2IM); 2 mL Amplimune subcutaneously (2SC); 5 mL Amplimune intramuscularly (5IM); 5 mL Amplimune subcutaneously (5SC); 5 mL saline intramuscularly (SalIM) and 5 mL saline subcutaneously (SalSC) on day 0 following transportation. Body temperature, body weight, concentrations of circulating pro-inflammatory cytokines (TNFα, IL-1ß, IL-6 and IL-12) and haematology parameters were measured at various times up to 96 h post-treatment. RESULTS: No adverse effects from Amplimune treatment were observed. Amplimune induced an increase in circulating cytokine TNFα concentrations, total white blood cell count and lymphocyte counts indicative of activation of the innate immune system without causing an excessive inflammatory response. CONCLUSIONS: Results confirm that Amplimune can be safely administered to beef cattle at the dose rates and via the routes of administration investigated here.

Reducing risk in basin scale CO2 sequestration: a framework for integrated monitoring design.

Injection of CO(2) into geological structures is a key technology for sequestering CO(2) emissions captured from the combustion of fossil fuels. Current projects inject volumes on the order of megatonnes per year. However, injection volumes must be increased by several orders of magnitude for material reductions in ambient concentrations. A number of questions surrounding safety and security of injection have been raised about the large scale deployment of geological CO(2) sequestration. They are site specific and require an effective monitoring strategy to mitigate risks of concern to stakeholders. This paper presents a model-based framework for monitoring design that can provide a quantitative understanding of the trade-offs between operational decisions of cost, footprint size, and uncertainty in monitoring strategies. Potential risks and challenges of monitoring large scale CO(2) injection are discussed, and research areas needed to address uncertainties are identified. Lack of clear guidance surrounding monitoring has contributed to hampering the development of policies to promote the deployment of large scale sequestration projects. Modeling provides an understanding of site specific processes and allows insights into the complexity of these systems, facilitating the calibration of an appropriate plan to manage risk. An integrated policy for risk-based monitoring design, prior to large scale deployment of sequestration will ensure safe and secure storage through an understanding of the real risks associated with large scale injection.

LC-MS/MS quantitative analysis of reducing carbohydrates in soil solutions extracted from crop rhizospheres.

A simple, sensitive, and specific analytical method has been developed for the quantitative determination of 15 reducing carbohydrates in the soil solution of crop rhizosphere. Reducing carbohydrates were derivatized with 1-phenyl-3-methyl-5-pyrazolone, separated by reversed-phase high-performance liquid chromatography and detected by electrospray ionization tandem mass spectrometry. Lower limits of quantitation of 2 ng/mL were achieved for all carbohydrates. Quantitation was performed using peak area ratios (analyte/internal standard) and a calibration curve spiked in water with glucose-d(2) as the internal standard. Calibration curves showed excellent linearity over the range 2-100 ng/mL (10-1,000 ng/mL for glucose). The method has been tested with quality control samples spiked in water and soil solution samples obtained from the rhizosphere of wheat and canola and has been found to provide accurate and precise results.

Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy.

OBJECTIVES: The effects of both temporary and permanent dual-chamber pacing (DCP) were evaluated in symptomatic pediatric patients with hypertrophic obstructive cardiomyopathy (HOCM) unresponsive to medications. BACKGROUND: Permanent DCP pacing can reduce left ventricular outflow tract (LVOT) gradient and relieve symptoms in adult patients with HOCM. METHODS: Ten patients (mean [+/-SD] age 11.1 +/- 6 years, range 1 to 17.5) with HOCM and a Doppler LVOT gradient > or = 40 mm Hg were studied. The seven patients showing hemodynamic improvement during temporary pacing at cardiac catheterization underwent surgical implantation of a permanent DCP system. The effects of permanent pacing were evaluated using a questionnaire, Doppler evaluation, treadmill testing and repeat cardiac catheterization. RESULTS: At initial cardiac catheterization, three patients failed to respond to temporary pacing (inadequate pace capture in two; congenital mitral valve abnormality in one). The remaining seven patients (70%, 95% confidence interval 38.0% to 91.7%, mean age 13 +/- years, range 4 to 17.5) showed a significant reduction (p < 0.05) in LVOT gradient, left ventricular systolic pressure and pulmonary capillary wedge pressure. After pacemaker implantation, these seven patients reported a significant reduction in dyspnea on exertion and exercise intolerance. Serial Doppler evaluation showed a significant reduction in LVOT gradient. Follow-up catheterization at 23 +/- 4 months in six patients (one patient declined restudy) showed a persistent decrease in LVOT gradient (53 +/- 13 vs. 16 +/- 11 mm Hg), left ventricular systolic pressure (149 +/- 16 vs. 108 +/- 14 mm Hg) and pulmonary capillary wedge pressure (18 +/- 2 vs. 12 +/- 4 mm Hg) versus preimplantation values. CONCLUSIONS: Permanent DCP is an effective therapy for selected pediatric patients with HOCM. Rapid atrial rates and intrinsic atrioventricular conduction, as well as congenital mitral valve abnormalities, may preclude effective pacing in certain patients.

Potent, long-acting luteinizing hormone-releasing hormone antagonists containing new synthetic amino acids: N,N'-dialkyl-D-homoarginines.

A new series of unnatural amino acids has been prepared and incorporated into antagonistic analogues of luteinizing hormone-releasing hormone (LH-RH), on the basis of the hypothesis that stabilization of a proposed phospholipid membrane interaction might yield analogues with high potency and a prolonged duration of action. Thus a series of NG,NG'-dialkyl-D-homoarginine analogues [H-D-hArg(R2)-OH; R = Me, Et, Pr, i-Pr, Bu, hexyl, cyclohexyl, (Et, Me2NPr)] was conveniently prepared by semisynthesis from D-Lys using the appropriate dialkylcarbodiimide. A number of the analogues that were prepared by using these new amino acid analogues exhibited very high potency and a prolonged duration of action. One of the most potent members of the series, [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,D-Ala10 ]LH-RH (detirelix), had an ED50 of 0.7 microgram in the rat antiovulatory assay when administered at noon on proestrus and only 2.5 micrograms when administered 24 h earlier, at noon on diestrus II. This antagonist is undergoing detailed biological and clinical evaluation.

Luteinizing hormone-releasing hormone antagonists containing very hydrophobic amino acids.

In a continuation of our studies on the effects of hydrophobic substitutions in analogues of luteinizing hormone-releasing hormone (LH-RH), we have synthesized LH-RH antagonists containing the very hydrophobic amino acid 3-(2-naphthyl)-D-alanine (D-Nal(2)). The D-Nal(2) substitution was found to be effective when incorporated in positions 3 and 6. The most potent analogue containing two D-Nal(2) residues was [N-Ac-Pro,D-pF-Phe,D-Nal(2)]LH-RH (ED50 = 2.2 micrograms, rat antiovulatory assay, propylene glycol-saline vehicle). This analogue also demonstrates that the N-Ac-Pro substitution is as effective as the more costly N-Ac-delta-Pro modification. Analogues containing D-Nal(2) in combination with the hydrophilic D-Arg residue in position 6 were prepared. Neither N-Ac-Pro at position 1 nor D-Nal(2) at position 3 was effective in combination with D-Arg. N-Ac-D-Nal(2) at position 1 gave a highly potent antagonist ([N-Ac-D-Nal(2),D-pF-Phe,D-Trp,D-Arg]LH-RH; ED50 = 2.4 micrograms) that exhibited a prolonged duration of action (ED50 = 9.0 micrograms, corn oil vehicle, dosing on diestrus II).

Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone.

The effect of increased hydrophobicity at position 6 of luteinizing hormone-releasing hormone (LH-RH) has been investigated by the incorporation of a series of 15 very hydrophobic, unnatural D-amino acids at this position. The unnatural amino acids studied can be considered analogues of phenylalanine with carbocyclic aromatic side chains consisting of substituted phenyl (e.g., 2,4,6-trimethylphenyl, p-biphenyl) or polycyclic aromatic (e.g., naphthalene, anthracene) units. When enzymatic resolution (subtilisin Carlsberg) of the most hydrophobic amino acids failed, the racemic amino acids were incorporated, and the diastereomeric LH-RH analogues were resolved by preparative high-performance liquid chromatography. The analogues were synthesized by the solid-phase technique. All of the synthetic compounds were very potent LH-RH superagonists, but [6-(3-(2-naphthyl)-D-alanine)]LH-RH, [6-(3-(2-naphthyl)-D-alanine), 7-(N alpha-methylleucine)]LH-RH and [6-(3-(2,4,6-trimethylphenyl)-D-alanine)]LH-RH appear to be among the most potent LH-RH agonist analogues yet reported when tested in a rat estrus cyclicity suppression assay designed to show the paradoxical antifertility effects of these compounds [ED50 approximately 7 x 10(-8) g; twice daily in saline]. These analogues are twice as potent as [D-Trp6,ProNHEt9]LH-RH in this assay system (i.e., approximately 200 times the potency of LH-RH).

Synthesis of a novel class of heteroaromatic amino acids and their use in the preparation of analogues of luteinizing hormone-releasing hormone.

A novel class of heterocyclic aromatic amino acids based on the 3-(2-benzimidazolyl)alanine system has been generated by chiral synthesis from D- or L-aspartic acid. The use of variously substituted o-phenylenediamines for condensation with the beta-carboxyl function of alpha-benzyl N-(benzyloxycarbonyl)-D-aspartate has led to a series of amino acids of graded hydrophobicity with a steric bulk similar to that of tryptophan. In a similar fashion, we have prepared 3-(2-benzothiazolyl)-D-alanine from o-aminothiophenol and 3-(2-benzoxazolyl)-D-alanine from o-aminophenol. Incorporation of these amino acids into the 6-position of luteinizing hormone-releasing hormone (LH-RH) led to a series of very potent agonist analogues (up to 160 times LH-RH potency), active in doses ranging from 0.1 to 0.5 microgram by twice daily injection in a rat estrus cyclicity suppression assay designed to show the paradoxical antifertility effects of these compounds.

Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197).

1. The contributions of alpha 2-adrenoceptors and 5-HT1A receptors to sexual behaviour in the rat have been re-evaluated by use of a highly potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197), yohimbine, idazoxan and the partial agonist at 5-HT1A receptors, 8-hydroxy-2(di-n-propylamino)-tetralin (8-OH-DPAT). 2. In a model where naive male rats were introduced to oestrogen-progesterone primed, sexually receptive female rats, delequamine (0.4-6.4 mg kg-1, p.o.) dose-relatedly increased the sexual behaviour score over the entire dose-range whereas yohimbine was effective at only one dose, 2 mg kg-1, p.o.. Idazoxan was active only at 2.5 and 5 mg kg-1, p.o. Yohimbine, but neither delequamine nor idazoxan, decreased ejaculation latency. 8-OH-DPAT (0.1 and 0.25 mg kg-1, s.c.) reduced the time, and the number of intromissions to ejaculation without affecting other parameters. A combination of delequamine (0.4 mg kg-1, p.o.) and 8-OH-DPAT (0.1 mg kg-1 s.c.) increased the percentage of rats mounting, intromitting and ejaculating, and reduced ejaculation latency and the number of intromissions. 3. In orchidectomized, sexually experienced rats exposed to sexually receptive females, delequamine, idazoxan and yohimbine increased the number of rats mounting, and there was a tendency to increase the number of animals intromitting, but no effect on ejaculatory behaviour. 4. In ovariectomized female rats brought to low level receptivity by priming with low dose injections of oestradiol benzoate and progesterone, delequamine, at 1.6 and 6.4 mg kg-1 p.o., increased lordosis, while yohimbine, at 2, 4 and 8 mg kg-1 p.o., reduced lordotic responses to sexually experienced males in a dose-dependent manner. 8-OH-DPAT at 0.1, 0.25 mg kg-1, s.c. reduced lordosis in a dose-dependent manner. 5. These findings may be explained on the basis that yohimbine is an alpha 2-adrenoceptor antagonist with affinity for 5-HT1A receptors and that the effects of 5-HT1A receptors may modulate the sexual behaviour responses to alpha 2-receptor antagonism in some models. Thus, in contrast to yohimbine, the highly-selective alpha 2-adrenoceptor antagonist, delequamine, was very effective in increasing the behavioural score in male and female rats over a wide dose-range.

Suppression of luteal progesterone secretion in the stumptailed macaque by an antagonist analogue of luteinizing hormone releasing hormone.

The dependence of progesterone secretion from the corpus luteum on pituitary gonadotrophin was examined in the cyclic stumptaile macaque by studying the effects of a single s.c. injection of a potent LH releasing hormone (LHRH) antagonist, [N-Ac-D-Nal(2)1, D-pCl-Phe2, D-Trp3, D-hArg(Et2)6, D-Ala10] LHRH. A dose of 100 micrograms antagonist/kg administered on days 9/10 of the luteal phase in three monkeys caused a marked temporary suppression of serum concentrations of LH and progesterone during the following 32h but levels still remained detectable and after 2 days serum hormone concentrations returned to the normal luteal-phase range. When the same animals were treated with 300 micrograms antagonist/kg at the same period during a subsequent cycle, serum LH levels were close to or at the limits of detection of the bioassay for the next 48h and progesterone concentrations declined steadily, reaching non-detectable values by 48h. In two monkeys the progesterone levels remained suppressed and they menstruated prematurely; in the third monkey the progesterone concentration rose to just above baseline and menstruation occurred at the expected time. Administration of 300 micrograms antagonist/kg on days 6/7 of the luteal phase in a further three monkeys also suppressed progesterone concentrations but not to baseline values, and after 2 days a normal progesterone profile was regained. These results suggest that the corpus luteum of the stumptailed macaque is largely dependent on pituitary gonadotrophin support during the mid to late luteal phase.

Suppression of luteal and placental function in pregnant baboons with agonist analogs of luteinizing hormone-releasing hormones.

Implantation of pelleted agonistic analogs of luteinizing hormone-releasing hormone (LH-RH) into six pregnant baboons, ranging between 14 and 21 days after mating in individual animals, resulted in two abortions: one at 39 and the other at 67 days after mating. Plasma progesterone levels were low in treated animals through the 23rd day after mating, in spite of rising levels of plasma chorionic gonadotropin. Plasma levels of progesterone then rose rapidly to normal in five of six animals. Plasma estradiol levels were low from treatment on in the late-aborting animal but were normal until 5 days before delivery in the early abortant. The profile of circulating chorionic gonadotropin was truncated in treated animals, which may be the first indication of a paradoxical effect of LH-RH agonist on the trophoblast.

Inability of continuous long-term administration of D-Nal(2)6-LHRH to abolish fertility in male rats.

A highly potent agonist of LHRH, [6-D-(2-naphthyl)-alanine]-LHRH, was administered chronically for 12 weeks to adult male rats by repetitive implantation of pellets, and its effects upon mating, fertility, and reproductive organ weights have been evaluated. Although significant declines in testicular (P less than 0.001) and epididymidal (P less than 0.001) weights were achieved, no effects on seminal vesicles, prostate, or pituitary weights were observed. After 12 weeks of continuous treatment, three of six agonist-treated rats were still successfully impregnating females. The decline in successful impregnation appeared to be related to the observed reduction in testicular spermatogenesis and in numbers of epididymal spermatozoa. The drug effects appeared reversible, as all six of the agonist-treated rats were fertile by the fifth week after cessation of treatment. Plasma levels of testosterone were markedly elevated immediately after implantation of each pellet and consistently, but not significantly, lowered during the inter-implantation periods. These observations, and the lack of effect on accessory organ weights, are consistent with the maintenance of libido in these treated rats. This is the second demonstration of a selective inhibition of spermatogenesis in the absence of a marked decline in gonadal steroidogenesis with this agent. As in the first demonstration using twice weekly injections, the degree of inhibition of spermatogenesis was insufficient to abolish fertility in the treated male rats.

Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist.

Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days. Although there was a rise in the circulating levels of the gonadotropins and of testosterone following the early injections of agonist, continued treatment caused a marked decline in acute response and basal levels of both LH and testosterone and smaller decreases in the acute FSH response. The decline in LH and testosterone was accompanied by decreases in testicular volume, ejaculated sperm count, sperm motility, ejaculate volume, and duration of ejaculation. The decline in these parameters was more rapid at 2.0 micrograms/kg than at 0.5 micrograms/kg. The profile of responses to 2.0 micrograms/kg could be superimposed on that previously shown for the injection of 10.0 micrograms/kg. At the end of treatment, prostate weights were 36% and 68% of vehicle-treated controls for high- and low-dose animals, respectively. Spermatogenesis was absent in the testes of all agonist-treated animals. Over the dose range tested, the dose-response on all parameters was characterized by a slower evolution to the same maximal effect, rather than by a partial effect. If these data can be extrapolated to man, they would suggest that administration of higher dose levels of LHRH agonists than presently reported should be explored.

Effects of an LHRH agonist analog upon sexual function in male dogs. Suppression, reversibility, and effect of testosterone replacement.

Male beagle dogs were injected once daily with 10 micrograms/kg of [6-D-(2-naphthyl)alanine]-LHRH (D-Nal(2)6-LHRH), a potent LHRH agonist, for periods up to 42 days, with recovery periods up to 172 days. Blood samples collected at regular intervals were assayed for LH, FSH, and testosterone; total ejaculates were collected and analyzed weekly, and animals were sacrificed at various intervals for sex organ weights and histology. The first injection of D-Nal(2)6-LHRH caused an acute elevation in plasma levels of LH, FSH, and testosterone, measured at 2 and 4 hours after the injection. This acute response to injection was attenuated with each successive injection and by two weeks no elevation was seen, suggesting a down-regulation of pituitary response. Basal levels of LH and testosterone were maximally depressed by four days of treatment. Testis volume, duration of erection, ejaculate volume, sperm count, sperm motility and testis volume all declined during treatment, with sperm count significantly lowered by two weeks and ejaculation volume becoming zero by five weeks of treatment. Spermatogenesis, assessed histologically, was partially suppressed at ten days and completely suppressed by 38 days of treatment. All parameters returned to normal following cessation of treatment. Recovery time was longer for the dogs treated for 42 days than for those treated for ten days. When testosterone was supplemented during 42 days of agonist treatment, basal plasma testosterone levels were maintained at the low end of the normal range. Testosterone supplementation did not prevent pituitary down-regulation, suppression of spermatogenesis, or the decrease in testis and epididymis weights, but prevented the decline in duration of erection. Ejaculate volume and sperm count declined more slowly with combination treatment than with agonist alone. During the decline in sperm count sperm motility was maintained with combination treatment. Injection of hCG into control and agonist treated dogs resulted in similar percentage increases in plasma levels of testosterone, although peak levels were greater in control than in treated animals. The data suggest a pituitary desensitization with this LHRH agonist in the dog but only a minor role for testicular desensitization.

Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer.

The release of the peptide hormone nafarelin, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)- D-alanyl-L-leucyl-L-arginyl-L-prolylglycinamide, a potent luteinizing hormone-releasing hormone (LHRH) agonist, from implants of the biodegradable copolymer poly(d,l-lactide-co-glycolide) (PLGA) has been studied both in vivo and in vitro. The release has a triphasic profile typical for bulk-eroding monolithic controlled-release systems, characterized by a secondary phase of lower release preceded and followed by phases of higher release. The primary factor controlling the peptide release profile is polymer erosion, which in turn may be controlled by modifying physical properties of the polymer such as the molecular weight or the ratio of the more hydrophobic lactic acid monomer to the less hydrophobic glycolic acid monomer. The duration of the secondary phase has been found to be directly proportional to the molecular weight of the copolymer, and the total duration as well as the duration of the secondary phase are both directly proportional to the monomer ratio. A system has been identified in which the secondary phase is sufficiently reduced to provide essentially continuous efficacy in the rat for greater then eight months, with partially effective levels of release of nafarelin continuing beyond 15 months.

Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres.

The performance in vivo of nafarelin acetate, a potent analogue of luteinizing hormone-releasing hormone, microencapsulated in poly(d,l-lactide-co-glycolide), was evaluated. The influence of polymer composition and molecular weight on the estrus-suppressing activity of the microspheres in female rats was determined. Compound release was shown to be effected by polymer erosion rather than by diffusion. A triphasic release of compound was observed, which was adjusted by altering the critical parameters of the polymer. A mechanism for the release of the compound was proposed. The primary release phase was compound loss by diffusion from the surface of the microspheres. The secondary phase of subeffective rates of release occurred concomitantly with polymer hydrolysis and a decrease in its molecular weight, although it remained insoluble. Dissolution of low-molecular weight fragments and erosion of the bulk of the polymer then initiated the tertiary phase of release of compound.

Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6)]LHRH, in rhesus monkeys. I.

Nafarelin acetate, [D-Nal(2)6]LHRH, a highly potent superagonist of luteinizing hormone-releasing hormone, was given intranasally to six female rhesus monkeys. Absorption was rapid and very reproducible, with peak levels occurring at 15-30 min and a bioavailability of approximately 2% relative to a subcutaneous dose. The nasal dose response was highly nonlinear. The nonlinearity was apparently associated with the absorption phase, since elimination profiles at all doses were similar.

Aortic root geometry: pattern of differences between leaflets and sinuses of Valsalva.

BACKGROUND AND AIMS OF THE STUDY: Growing interest in aortic root replacement with the use of stentless auto-, homo- and xenografts, and new developments in aortic valve conservation demand a deeper understanding of the normal aortic root anatomy. METHODS: Ten cryopreserved human aortic roots were pressurized, fixed and measured directly (leaflet free edge and attachment) and using three-dimensional computed tomography imaging software (sinus of Valsalva height and volume). RESULTS: The mean of the measurements of all four parameters yielded a pattern in which the non-coronary sinus (N) structures had the greatest dimensions followed by the right (R) and then the left (L). Non-parametric ANOVA on each of these parameters also showed significant differences among the sinuses yielding a pattern of N > R > L. This pattern determined an angle of tilt between the plane at the base (annulus) and the plane intersecting the sinotubular junction with a mean value of 11 degrees. Linear regression indicated that this angle did not depend on the size of the base (annulus). CONCLUSIONS: The data showed a geometric pattern of the aortic root, with the structures of the non-coronary sinus being the largest followed by the right and then the left. The possible hemodynamic relevance and surgical implications of these findings need to be explored.